Company hosting in-person R&D day event, focused on atrioventricular interval modulation (“AVIM”) therapy, including the unmet need in hypertension, mechanism […]
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering […]